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Abstract In a previous work, we tested a series of chalcone
derivatives as possible anti-inflammatory compounds. We now
investigate the effects of three of those compounds, CH1, CH8
and CH12, on nitric oxide and prostanoid generation in mouse
peritoneal macrophages stimulated with lipopolysaccharide and
in the mouse air pouch injected with zymosan, where they showed
a dose-dependent inhibition with inhibitory concentration 50%
values in the WM range. This effect was not the consequence of a
direct inhibitory action on enzyme activities. Our results
demonstrated that chalcone derivatives inhibited de novo
inducible nitric oxide synthase and cyclooxygenase-2 synthesis,
being a novel therapeutic approach for inflammatory diseases.
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1. Introduction
Macrophages participate in host defense, immunity and in-
£ammatory responses, where they are potently activated re-
sulting in the production of cytokines, oxygen and nitrogen
species and eicosanoids. These in£ammatory and immuno-
modulatory mediators cause diverse biological e¡ects. In
macrophages, bacterial lipopolysaccharide (LPS) alone or in
combination with cytokines like interferon-Q (IFNQ) is one of
the best-characterized stimuli to induce the transcription of
genes encoding pro-in£ammatory proteins, resulting in cyto-
kine release and synthesis of enzymes such as cyclooxygenase-
2 (COX-2) [1] and inducible nitric oxide synthase (iNOS) [2].
The inducible isoform COX-2 would be responsible for the
high prostanoid generation during in£ammatory responses [3],
although the participation of COX-1, constitutively expressed
in mammalian cells, has also been suggested [4].
Reactive nitrogen intermediates such as nitric oxide (NO)
are shown to play a central role in in£ammatory and immune
reactions. Apart from their vascular e¡ects, NO and derived
oxidants, such as peroxynitrite, contribute to tissue injury. In
addition, NO can enhance the production of a variety of other
in£ammatory mediators, including tumor necrosis factor-K
(TNFK), interleukin-1 and reactive oxygen intermediates
which participate directly and indirectly in the macrophage-
dependent in£ammatory response [5].
Activated macrophages appear to be the main cellular
source of iNOS and these cells contribute signi¢cantly to the
induction of iNOS and generation of NO after LPS admin-
istration to mice [6]. LPS activation of murine macrophages
leads to co-induction of iNOS and COX-2 [7,8], which in-
volves common mechanisms such as tyrosine phosphorylation
[9]. A number of studies have indicated that iNOS and COX-2
pathways are also co-induced in vivo in di¡erent in£ammation
models [10^14].
Recently, we have investigated the e¡ects of a series of
chalcone derivatives on human neutrophil functions in vitro
as well as on eicosanoid release and TNFK production in mice
[15]. The present study was designed to determine if three of
these chalcone derivatives (Fig. 1) could modulate the produc-
tion of NO and/or prostaglandins (PGs) in vitro using mouse
peritoneal macrophages, as well as in vivo, in the mouse air
pouch.
2. Materials and methods
2.1. Materials
[5,6,8,11,12,14,15(n)-3H]PGE2 and L-[2,3,4,5-3H]arginine monohy-
drochloride were from Amersham Iberica (Madrid, Spain).
[35S]methionine was from ICN (CA, USA). iNOS and COX-2 poly-
clonal antiserum and NS398 were purchased from Cayman Chem.
(MI, USA). The rest of the reagents were from Sigma (MO, USA).
2.2. Isolation and culture of murine peritoneal macrophages
Female Swiss mice weighing 25^30 g were used to obtain highly
puri¢ed peritoneal macrophages. Cells were harvested by peritoneal
lavage 4 days after intraperitoneal injection of 1 ml 10% thioglycolate
broth and were resuspended in culture medium (120 mM NaCl,
4.7 mM KCl, 1.2 mM CaCl2W7H2O, 1.2 mM KH2PO4, 25 mM
NaHCO3, 10 mM HEPES, 1 mM L-arginine and 10 mM glucose),
supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/
ml penicillin, 100 Wg/ml streptomycin and incubated at 37‡C for 2 h
[16]. The adherent cells were used to perform the following experi-
ments. The mitochondrial-dependent reduction of 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan was
used to assess the possible cytotoxic e¡ects of test compounds on
murine peritoneal macrophages [17].
2.3. Nitrite (NO32 ) and PGE2 production
Murine peritoneal macrophages (2U105/well) were co-incubated
with test compounds and Escherichia coli LPS (serotype 0111:B4)
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(10 Wg/ml) at 37‡C for 24 h. Nitrite and PGE2 accumulation were
measured in 24 h supernatants.
In a di¡erent set of experiments, culture medium of 24 h LPS-
stimulated macrophages (4U105/well) in the absence or presence of
test compounds was removed and medium supplemented with L-argi-
nine (0.5 mM) and arachidonic acid (10 WM) was added for a further
2 h incubation with or without test compounds, respectively. Super-
natant was collected for the measurement of nitrite and PGE2 accu-
mulation for the last 2 h. The nitrite concentration as re£ection of NO
release was assayed £uorometrically [18]. The amount of nitrite was
obtained by extrapolation from a standard curve with sodium nitrite
as a standard. PGE2 levels were assayed by a radioimmunoassay [19].
2.4. NOS and COX activity in broken cell preparations
After stimulation with LPS (10 Wg/ml) for 24 h, murine peritoneal
macrophages (107/ml) were collected and after centrifugation, the cell
pellet was sonicated and centrifuged as previously described [13]. High
speed supernatant and pellet were used for NOS and COX assays,
respectively. NOS activity was determined by assessing the conversion
of L-[3H]arginine to L-[3H]citrulline in the cytosolic cellular fraction,
as described by Mitchell et al. [20]. COX-2 activity was assayed as
previously described [21] and PGE2 levels were determined by a radio-
immunoassay [19]. The protein content was quanti¢ed by the Brad-
ford technique [22].
2.5. Immunoprecipitation assay
Cellular lysates were obtained from mouse peritoneal macrophages
incubated with LPS (10 Wg/ml) and IFNQ (10 U). At the indicated
times and doses, cells (1.7U106/well) were lysed with lysis bu¡er (1%
Triton X-100, 1% deoxycholic acid, 20 mM NaCl and 25 mM Tris,
pH 7.4). For immunoprecipitation assays, macrophages were stimu-
lated with appropriate concentrations of LPS and/or IFNQ for di¡er-
ent times in the absence or presence of test compounds. Then, cells
were shifted to methionine-free RPMI 1640 medium and pulse-la-
belled for 3 h with 25 WCi/ml [35S]methionine (trans 35S-label). Radio-
labelled iNOS and COX-2 isoenzymes present in the cellular lysate
were immunoprecipitated with speci¢c polyclonal antibodies against
recombinant iNOS and COX-2 and subjected to SDS-PAGE under
reducing conditions. After £uorography, radioactive bands were ex-
cised and quanti¢ed in a L-counter.
2.6. Mouse air pouch model
An air pouch was performed in female Swiss mice (25^30 g) as
previously described [21]. Chalcone derivatives and dexamethasone
(0.1 and 0.01 Wmol/pouch) were injected 1 h before and 8 h after
zymosan. 24 h after zymosan administration, the animals were killed
by cervical dislocation and the exudate in the pouch was collected
with 1 ml of saline. Leukocytes present in exudates were measured
using a Coulter counter. After centrifugation of exudates (1200Ug at
4‡C for 10 min), the supernatants were used to measure nitrite and
PGE2 levels as described above.
2.7. Statistical analysis
Statistical evaluation included one-way analysis of variance
(ANOVA) followed by Dunnett’s test for multiple comparisons.
P-values of P6 0.05 (*) or P6 0.01 (**) were taken as signi¢cant.
Results are shown as mean þ S.E.M. for n experiments. Inhibitory
concentration 50% (IC50) values were calculated from at least four
signi¢cant concentrations.
3. Results
3.1. E¡ects of chalcone derivatives on nitrite and PGE2
production in mouse peritoneal macrophages
In preliminary experiments, all chalcones belonging to the
series reported by Herencia et al. [15] were screened at the
concentration of 10 WM for their activity on nitrite and
PGE2 production in mouse peritoneal macrophages stimu-
lated by LPS (data not shown). The most active chalcone
derivatives (CH1, CH8 and CH12) were selected for further
studies. These compounds inhibited nitrite and PGE2 produc-
tion dose-dependently (Fig. 2) with IC50 values in the WM
range. CH8 and CH12 exhibited a similar behavior, with a
higher potency on PGE2. In contrast, CH1 was more potent
on the nitrite production. As expected, aminoguanidine re-
duced the nitrite accumulation (IC50 = 25.1 WM) without a
signi¢cant e¡ect on PGE2 levels at 100 WM. NS398 inhibited
to a great extent PGE2 production (IC50 = 3.1 nM), whereas
dexamethasone reduced very signi¢cantly both metabolites
(IC50 = 35.8 nM and IC50 = 1.0 nM for nitrite and PGE2, re-
spectively). Essentially the same inhibition patterns were ob-
served when the cells were stimulated with LPS+IFNQ (data
not shown). These compounds did not a¡ect the cellular via-
bility, as assessed by mitochondrial reduction of MTT after
24 h treatment (data not shown), indicating that they were not
cytotoxic.
3.2. E¡ects of chalcone derivatives on NOS and COX activities
in mouse peritoneal macrophages
To determine if the inhibition of nitrite and PGE2 produc-
tion was either due to an interference with the enzyme induc-
tion by LPS or due to a direct action of these compounds on
NOS and COX activities, the following experiments were per-
formed. Chalcone derivatives were incubated with cells after
the induction of these enzymes by LPS. Cells were treated
with LPS for 24 h to allow the induction and expression of
iNOS and COX-2 and then, were washed with culture me-
dium. Test compounds were added at 10 WM and incubated
for 2 h in fresh culture medium supplemented with L-arginine
and arachidonic acid. No signi¢cant reduction of either nitrite
nor PGE2 production during these 2 h was observed for the
chalcone derivatives (Table 1). Nevertheless, aminoguanidine,
a known inhibitor of NOS activity, caused a very signi¢cant
reduction of nitrite production (50%) without a¡ecting the
PGE2 level, whereas the selective COX-2 inhibitor NS398
caused a marked inhibition of PGE2 production (78%). The
Fig. 1. Structures of chalcone derivatives CH1, CH8 and CH12.
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corticosteroid dexamethasone, an inhibitor of iNOS and
COX-2 gene expression, failed to signi¢cantly modify the lev-
els of both metabolites.
In another set of experiments, chalcone derivatives were
present during the 24 h LPS treatment of cells. After washing
with fresh medium, macrophages were incubated for a further
2 h. The nitrite and PGE2 production during these 2 h was
signi¢cantly reduced by chalcones and dexamethasone (Table
1). This suggests that the presence of chalcone derivatives
during the induction period can a¡ect iNOS and COX-2 ex-
pression levels.
To corroborate our results on enzyme activity, we examined
the e¡ects of chalcone derivatives on broken cell preparations.
The high speed supernatant fraction of 24 h LPS-stimulated
cells was used as the source of iNOS. These compounds at
10 WM were inactive on citrulline generation. In contrast,
aminoguanidine reduced the levels of citrulline by 56% (Table
2). The assay performed in absence of calcium gave no sig-
ni¢cant di¡erences, but in the absence of NADPH, there was
a signi¢cant reduction of the citrulline production (by 39%).
The latter e¡ect con¢rms that this enzyme activity shows a
good correlation with the well-characterized properties of
iNOS. The microsomal cellular fraction (enriched in COX
enzyme) was used to assay the PGE2 production. Only
NS398 caused a signi¢cant inhibition of the generation of
PGE2 in this subcellular preparation.
3.3. E¡ects of chalcone derivatives on iNOS and COX-2
protein expression in mouse peritoneal macrophages
Data described above suggest that the inhibition of NO and
PGE2 production by some of these chalcones in peritoneal
macrophages occurs at the level of enzyme expression.
As expected [2], a synergy between LPS (10 Wg/ml) and
IFNQ (10 U) was obtained in our experimental system and,
thus, it was selected for further studies. To characterize the
time-course of enzyme synthesis, mouse peritoneal macro-
phages were stimulated with LPS+IFNQ during 6, 12 and
24 h in medium free of methionine, containing [35S]methionine
(25 WCi/ml) for the last 3 h of the experiment. Cells were lysed
and the supernatants were used to determine iNOS and COX-
2 by immunoprecipitation with speci¢c antibodies. In parallel
experiments, we assayed nitrite and PGE2 accumulation in
di¡erent time-courses of cell stimulation. Fig. 3a shows a
peak in de novo iNOS synthesis at 12 h. At this time, signi¢-
Fig. 2. Dose-response curves of nitrite and PGE2 inhibition by
tested compounds in stimulated peritoneal macrophages. Cells were
incubated with LPS in the presence of inhibitors for 24 h and super-
natants were used to determine mediator levels. Each value repre-
sents the mean þ S.E.M. for more than three triplicate experiments.
Table 1
E¡ects of chalcone derivatives and reference compounds on NOS and COX activity in peritoneal macrophages
A (2 h treatment) B (24 h treatment)
NO32 (ng/ml) PGE2 (ng/ml) NO
3
2 (ng/ml) PGE2 (ng/ml)
24 h without LPS 1.9 þ 0.3** 2.1 þ 0.2** 6.8 þ 0.5** 1.2 þ 0.2**
Control 59.2 þ 6.2 8.6 þ 0.6 53.0 þ 3.1 6.7 þ 0.3
CH1 (10 WM) 58.9 þ 6.9 7.1 þ 0.7 17.9 þ 1.2** 5.1 þ 0.6*
CH8 (10 WM) 50.6 þ 8.6 7.4 þ 0.7 10.8 þ 1.5** 3.2 þ 0.6**
CH12 (10 WM) 51.3 þ 4.8 7.5 þ 0.5 6.2 þ 0.2** 2.2 þ 0.2**
Aminoguanidine (100 WM) 30.5 þ 3.5** 7.8 þ 1.0 17.5 þ 1.9** 6.3 þ 0.4
NS398 (10 WM) 77.1 þ 6.5 3.5 þ 0.5** 43.0 þ 2.3 1.4 þ 0.1**
Dexamethasone (1 WM) 39.7 þ 3.8 6.9 þ 0.7 6.4 þ 0.2** 0.9 þ 0.1**
A: Cells were stimulated with LPS for 24 h. After washing the cells, test compounds were added and incubated for 2 h in the presence of
L-arginine (0.5 mM) and arachidonic acid (10 WM).
B: Cells were co-incubated with LPS and test compounds for 24 h. After washing the cells, incubation proceeded for 2 h in the presence of
L-arginine (0.5 mM) and arachidonic acid (10 WM).
Results are the mean þ S.E.M. of at least three independent experiments assayed in triplicate. *P6 0.05 and **P6 0.01 compared with the con-
trol.
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cant levels of nitrite were detected and the maximal accumu-
lation of nitrite was reached at 18 h. As shown in Fig. 3b,
COX-2 protein synthesis was similar during all periods as-
sayed and protein synthesis and PGE2 levels were detected
at an earlier time than iNOS and nitrite.
We then quanti¢ed de novo iNOS and COX-2 protein syn-
thesis in the presence of the three chalcone derivatives (10
WM) and reference inhibitors dexamethasone (10 WM),
NS398 (10 WM) and aminoguanidine (100 WM), in 12 h
LPS+IFNQ-stimulated cells. Results obtained by £uorography
(see ¢gure inserts) and its protein quanti¢cation (Fig. 4a and
b) showed that CH12 a¡ected iNOS (66.9% inhibition) and
COX-2 (51.4%) synthesis, whereas CH8 only a¡ected iNOS
(54.9%) and CH1 showed a lower inhibition of iNOS (32.1%)
Fig. 3. Time-course of nitrite and PGE2 production and iNOS and
COX-2 protein synthesis by macrophages stimulated with LPS+IFNQ.
Aliquots of supernatants were assayed for nitrite (a) and PGE2 (b)
production at indicated times. Bars indicate de novo synthesis of en-
zymes iNOS (a) and COX-2 (b) in immunoprecipitates. Cells were
washed 3 h before the indicated times with fresh methionine-free
medium and medium containing 25 WCi [35S]methionine was added
for the last 3 h of the experiment. Cellular lysate was used to evalu-
ate the immunoprecipitation assay. The quanti¢cation data and in-
sert are representatives of three di¡erent experiments.
Fig. 4. De novo protein synthesis, (a) iNOS and (b) COX-2, by
mouse peritoneal macrophages stimulated for 12 h with LPS+IFNQ
in the presence of test compounds (chalcones at 10 WM, dexametha-
sone at 10 WM, NS398 at 10 WM and aminoguanidine at 100 WM).
Cells were washed 3 h before the indicated time with fresh methio-
nine-free medium and medium containing 25 WCi [35S]methionine
was added for the last 3 h of the experiment. Cellular lysate was
used to evaluate the immunoprecipitation assay. Quanti¢cation data
are mean þ S.E.M. of three di¡erent experiments. DEX = dexametha-
sone, NS = NS398, AG = aminoguanidine, *P6 0.05 and **P6 0.01.
Table 2
E¡ects of chalcone derivatives and reference compounds on NOS and COX activities in broken cells preparations
Citrulline (pmol/mg) PGE2 (ng/mg)
Without LPS 3.2 þ 0.1**
Control 775.6 þ 58.8 9.6 þ 0.3
CH1 (10 WM) 679.0 þ 40.4 8.9 þ 0.8
CH8 (10 WM) 796.6 þ 47.2 9.9 þ 0.4
CH12 (10 WM) 645.2 þ 44.2 9.3 þ 0.3
Aminoguanidine(100 WM) 343.4 þ 19.8** N.D.
NS398 (1 WM) N.D. 7.2 þ 0.3*
Microsomal and cytosolic fractions from 24 h LPS-stimulated cells were used to determine NOS and COX activities as citrulline (pmol/mg pro-
tein) and PGE2 (ng/mg protein) generated, respectively, as indicated in Section 2.
Results are the mean þ S.E.M. of at least three independent experiments assayed in triplicate. *P6 0.05 and **P6 0.01 compared with the con-
trol. N.D., not determined.
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and COX-2 (18.0%). As expected, dexamethasone reduced the
iNOS (49.2%) and COX-2 (65.9%) synthesis, whereas neither
NS398 nor aminoguanidine, at the dose assayed, a¡ected sig-
ni¢cantly the protein synthesis, as clear evidence that their
action does not depend on this mechanism.
3.4. In vivo e¡ects of chalcone derivatives (mouse air pouch
model)
To corroborate in vivo the inhibitory e¡ect observed in
isolated macrophage cells, we administered the compounds
intrapouch and determined the cell accumulation and media-
tors release in the zymosan-injected mouse air pouch. Chal-
cone derivatives (at 0.1 and 0.01 Wmol/pouch) did not a¡ect
the cellular migration except CH8. Nevertheless, they reduced
to a great extent nitrite and PGE2 levels in the exudate of the
pouch (Table 3). As expected, dexamethasone caused a
marked reduction in those metabolites and besides, reduced
the cellular accumulation.
4. Discussion
NO produced by iNOS has been implicated in the patho-
physiology of in£ammatory and immune diseases. It is known
that iNOS participates in the production of pathological
changes in adjuvant arthritis and its inhibition would attenu-
ate these changes [23]. iNOS inhibition also results in the
control of the in£ammatory response in other models includ-
ing granuloma formation by subcutaneous implantation in
rats of carrageenin-soaked sponges [24], chronic granuloma-
tous colitis in rats [25] or the delayed paw swelling induced by
carrageenin in mice [26]. In humans, the production of NO by
activated macrophages or neutrophils can be an index for
human bronchial in£ammation and a mechanism for amplify-
ing asthmatic in£ammation [27]. There is also evidence of an
increased NO production in infectious gastroenteritis [28] and
rheumatoid arthritis [28,29], where peroxynitrite has also been
detected [30]. NO is also implicated in human ostheoarthritis,
classically considered as a non-in£ammatory disease, where it
may be involved in cartilage destruction [31].
We have shown that three novel chalcone derivatives inhibit
dose-dependently NO and PGE2 production in vitro, in
mouse peritoneal macrophages stimulated by LPS and also
in vivo, in the mouse air pouch injected with zymosan, with
some di¡erences in potency and selectivity. Our results indi-
cate that in vitro, CH12 and CH8 are more potent on PGE2
than on nitrite levels, whereas CH1 is more potent as inhibitor
of nitrite. These compounds had no direct inhibitory e¡ect on
iNOS or COX-2 activities, as judged either in intact cells after
induction of these enzyme or by assays with broken cells. In
our previous studies, it was shown that they are not COX-1 or
phospholipase A2 inhibitors [15]. Besides, the addition of
exogenous substrates does not seem to a¡ect their inhibitory
e¡ects in a signi¢cant way. Our results thus suggest that these
chalcones modify the induction of iNOS and COX-2.
Characterization of the synthetic process of these proteins
led us to select LPS+IFNQ as stimulus and 12 h as the time for
maximal detection of synthesis. The data presented here dem-
onstrate that inhibition of de novo synthesis of iNOS may be
the major mechanism responsible for the observed inhibition
of NO production by the three chalcone derivatives. These
compounds could selectively inhibit the enhanced expression
of this enzyme in in£ammation. Inhibition of COX-2 synthesis
may account for the inhibitory e¡ect on PGE2 generation of
CH12 and at least in part of CH1. In contrast, our results on
the synthesis of COX-2 exclude this mechanism for CH8.
Nevertheless, we have observed that the presence of this com-
pound during the induction process (24 h LPS treatment) can
modify the activity of COX-2.
NO may act in an autocrine manner to modulate the cel-
lular response to in£ammation and inhibition of NO produc-
tion would result in inhibition of PG generation [7]. Never-
theless, this is a matter of debate since the results obtained
vary according to the cell type considered and experimental
conditions[8,32^35]. The in vivo situation can be more di⁄cult
to evaluate, specially if non-selective inhibitors are used [36].
COX metabolites can also in£uence the NO production in
some cases, since PGE2 can exert a negative feedback by in-
hibition of iNOS expression [37] due to an interference with
nuclear factor UB (NF-UB) activation [38]. In our experimen-
tal protocol, in murine peritoneal macrophages, we found no
evidence for a direct iNOS-COX interaction, as previously
shown in cell lines of murine macrophages [34,35]. It is thus
unlikely that such a mechanism can be relevant for the inhib-
itory e¡ects of these chalcones in LPS-stimulated murine peri-
toneal macrophages.
NO overproduction can be controlled by NOS inhibitors.
Nevertheless, at doses normally used, they inhibit frequently
constitutive isoforms, which leads to hypertension and a de-
creased local blood £ow [39] or progressive leukocytosis and
in£ammation in the ileum after chronic treatment [40]. In
addition, chronic inhibition of NOS can result in an increased
iNOS expression followed by overproduction of NO upon
Table 3
E¡ects of chalcone derivatives and dexamethasone on cell accumulation, nitrite and PGE2 levels in exudates of a 24 h zymosan-injected mouse
air pouch
Doses (Wmol/pouch) Cell accumulation (U106 cells/ml) Nitrite (ng/ml) PGE2 (ng/ml)
Saline 3.2 þ 0.3** 2.3 þ 0.6** 0.5 þ 0.1**
Control 17.4 þ 1.3 100.1 þ 13.9 14.5 þ 1.1
CH1 0.1 16.7 þ 1.3 36.5 þ 6.5** 5.1 þ 0.7**
0.01 16.5 þ 1.9 54.9 þ 6.9* 5.7 þ 0.8**
CH8 0.1 11.1 þ 0.7** 40.9 þ 6.9** 3.2 þ 0.7**
0.01 12.8 þ 0.6* 58.4 þ 4.7* 5.4 þ 1.1**
CH12 0.1 14.9 þ 0.7 45.8 þ 6.9** 4.8 þ 1.1**
0.01 15.5 þ 0.7 56.1 þ 5.6* 5.3 þ 0.7**
Dexamethasone 0.1 10.4 þ 1.0** 28.3 þ 3.3** 0.9 þ 0.1**
0.01 12.5 þ 0.8* 40.5 þ 7.2* 4.1 þ 0.5**
Compounds were administered at 0.1 and 0.01 Wmol/pouch, at times indicated in Section 2. Results are the mean þ S.E.M. for 6^12 animals.
*P6 0.05 and **P6 0.01 compared with the control (zymosan-injected air pouches).
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removal of the inhibitor [41]. These chalcone derivatives may
selectively inhibit the enhanced expression of iNOS to control
high production of NO during in£ammatory or immune con-
ditions. It is known that activation of NF-UB is crucial for the
increase in iNOS gene expression and some anti-oxidants are
able to control this redox-sensitive step, although mechanisms
other than interaction with free radicals may be implicated
[42]. Whether these chalcones inhibit de novo protein synthe-
sis by modi¢cation of nuclear factors or by other mechanisms
remains to be determined.
In vivo, inhibitory e¡ects on nitrite and PGE2 levels were
also observed for the three chalcones. CH12 and CH8 exhib-
ited an inhibitory behavior correlated with their in vitro re-
sults on nitrite and PGE2 accumulation in 24 h LPS-stimu-
lated mouse peritoneal macrophages, whereas CH1 was more
potent than expected and reduced both metabolites in a sim-
ilar way. In this model, the mouse air pouch injected with
zymosan, iNOS and COX-2 is induced in several cell types,
including migrating leukocytes and also macrophages lining
the pouch [14], raising the possibility that the activity of this
compound can be di¡erent according to the cell involved. On
the other hand, CH8 was able to decrease leukocyte migration
in vivo. It is interesting to note that this compound showed an
inhibitory action on human 5-lipoxygenase and it also reduced
TNFK levels in mice [15], which suggests that di¡erent mech-
anisms could be involved in its anti-in£ammatory e¡ect.
COX activity is the main therapeutic target for non-steroi-
dal anti-in£ammatory drugs. Nevertheless, COX inhibition
can result in an increased COX-2 expression [37] and suppres-
sion of treatment with reversible COX-2 inhibitors would re-
sult in a transient overproduction of PGs [43]. Furthermore,
some inhibitors of COX-1 and COX-2 would be less e¡ective
at more in£amed sites, since the supply of arachidonic acid
can determine their e¡ectiveness [44]. These chalcone deriva-
tives able to control NO and PG production by mechanisms
other than enzyme inhibition have a potential role in modu-
lating the in£ammatory process.
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